EC
PRTK

EcoR1 Capital’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

EcoR1 Capital’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-78,958
Closed -$3.04M – 26
2014
Q4 		$3.04M Buy
+78,958
New +$1.89M 1.54% 18

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

EcoR1 Capital's PRTK Position: Q1 2015 in Review

EcoR1 Capital sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2015, closing a stake of 78,958 shares — an estimated $3.04M sold.

EcoR1 Capital first reported a position in PRTK in Q4 2014 and held it in 1 quarter. The position peaked at $3.04M in Q4 2014. 38 funds tracked by Wall St. Rank hold PRTK as of Q1 2015.

  • EcoR1 Capital reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • EcoR1 Capital sold 78,958 Paratek Pharmaceuticals, Inc. shares in Q1 2015, an estimated $3.04M.
  • EcoR1 Capital first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • EcoR1 Capital's Paratek Pharmaceuticals, Inc. position peaked at $3.04M in Q4 2014.
  • 38 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2015.

Based on EcoR1 Capital's 13F filing for Q1 2015, filed 15 May 2015.